Abstract
Objective: To evaluate the efficacy and safety of tirofiban hydrochloride in the treatment of ischemic stroke with thrombolytic therapy. Method: Two hundred patients with acute ischemic stroke thrombolysis were randomly divided into the experimental group and the control group. The experimental group was given tirofiban with the addition of rtpa in the control group and the therapeutic effects of the two groups were compared. Results: In comparison with the control group, the NIHSS improvement rate was 98% in the experimental group within 14 days. The platelet aggregation rate and efficacy in the experimental group were significantly reduced than the control group (P < 0.01). The major adverse reaction in the two groups was hemorrhage with an incidence rate of 3%. Conclusion: Tirofiban hydrochloride is a highly effective and selective platelet glycoprotein IIb/IIIa receptor inhibitor, which is safe and effective in combination with heparin and aspirin.